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Abstract The aim of the present study was to evaluate
the expression of hedgehog (Hh) signaling molecules and
the chemotactic activity of Sonic hedgehog (Shh) in
monocytes from control (CTR) and diabetic patients with
or without coronary artery disease (CAD). Previously
several studies demonstrated that exogenous administration
of Shh can induce angiogenesis and accelerate repair of
ischemic myocardium and skeletal muscles. Blood samples
were collected from (1) CTR (n = 25); (2) patients with
stable CAD without diabetes mellitus (CAD-DM,
n = 10); and (3) with stable CAD with DM (CAD?DM,
n = 15). Monocytes were isolated by Percoll gradient and
subjected to PCR and chemotaxis analysis. Hh signaling
molecules were expressed in human monocytes, and Shh-
induced monocyte chemotaxis. Shh-stimulated migration
of monocytes from CTR measured 172.5 ± 90% and a
maximal stimulation was observed at Shh concentration of
1 lg/ml. However, Shh failed to induce migration of
monocytes from CAD?DM (94.3 ± 27%, P\0.001 vs.
CTR). The impaired response to Shh was associated with
strong transcriptional upregulation of the receptor Ptc,
while expression of downstream molecules was not altered.
Moreover, Ptc is strongly expressed in macrophages of
human aortic atherosclerotic plaque. Thus, Shh is a potent
chemoattractant for monocytes and it activates classical
signaling pathways related to migration. The Shh signaling
was negatively affected by DM which might be involved in
the pathogenesis of DM-related complications.
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Introduction
The Hedgehog (Hh) pathway is highly conserved in evo-
lution and Hh proteins are essential for cell fate decisions
during development and homeostasis of adult tissues.
Three proteins compose the Hh family: Sonic (Shh), Indian
(Ihh) and Desert (Dhh) hedgehogs. All Hh proteins bind to
a surface receptor complex comprised of two transmem-
brane proteins Patched (Ptc), a receptor for Hh proteins and
Smoothened (Smo), a signal transducer. It has been dem-
onstrated that all Hh members Shh, Ihh and Dhh proteins
bind the receptor Ptc with similar afﬁnity, however, they
vary with regard to their potency. The rank order of
potency was generally Shh C Ihh C Dhh [27]. The Hh
signal is then mediated by the Gli family transcription
factors (Gli 1–3), which regulate the expression of different
target genes [10].
There is increasing evidence for the role of Hh signaling
in vascularization and neovascularization. Recently, it has
been shown that activation of Hh signaling is critical for
coronary development and sufﬁcient to promote formation
of coronary vessels in the embryonic and adult heart [13,
22, 29]. Shh gene therapy could promote both angiogenesis
and arteriogenesis and protect from ischemic injury in
rodent and large animal models [21]. However, the
mechanism how Shh induces neovascularization is still
unknown. It has been shown that blood circulating mono-
nuclear cells play an important role in both artheriogenesis
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DOI 10.1007/s00395-009-0047-xand angiogenesis [15, 32]. They adhere to the arterial wall,
inﬁltrate and stimulate vessel growth in the ischemic tissue
by the release of cytokines, growth factors and proteases.
Several recent studies have suggested a role of Hh sig-
naling in the control of motility and migration of multiple
cell types. Hedgehog proteins act as a chemoattractant on
isolated axons, guide neuronal migration during embryonic
development [6], serves as an attractive cue to guide germ
cell migration through the embryo to form primitive gonad
in Drosophila [12], promote the migration of endothelial
progenitor cells [1], rat activated pancreatic stellate cells
[33], embryonic endothelial cells and ﬁbroblasts [18]a s
well as optic nerve oligodendrocyte precursors [24].
However, nothing is known about migration control of
immune cells by Hh proteins. Here, we tested the
hypothesis whether Shh stimulates monocyte chemotaxis.
Our results demonstrate that Shh is a potent chemoattrac-
tant for peripheral monocytes and it activates classical
signaling pathways related to cellular migration such as
G-proteins or PI3K. Moreover, we provide the ﬁrst piece of
evidence that pathological conditions such as diabetes
mellitus (DM) signiﬁcantly impair Shh-induced chemo-
taxis, which is accompanied by elevated expression levels
of Ptc. Thus, these data indicate that the Hh signaling
pathway (1) is involved in monocyte biology and (2) is
negatively affected by the cardiovascular risk factor DM.
Methods
Study population
This study was performed with the approval of the medical
ethics committee of the University Hospital of Maastricht
(The Netherlands), and conforms to the principals outlined
in the Declaration of Helsinki. All enrolled subjects gave
their written informed consent. Three groups of subjects
were studied: (1) Patients with stable coronary artery dis-
ease without diabetes mellitus (CAD-DM, n = 10). Stable
CAD was deﬁned as history of stable angina pectoris or
history of PCI and/or CABG. Patients with acute myocar-
dial infarction and/or recent surgical intervention (less then
6 months) were excluded. All patients had a recent coro-
nary angiogram. (2) CAD patients with diabetes mellitus
(CAD?DM, n = 15). The diagnosis of DM was veriﬁed
by history of DM, elevated fasting glucose level and/or
increased concentration of glycosylated HbA1c. (3) Control
subjects (CTR) without any history or clinical signs of
Table 1 Clinical characteristics
of control subjects and patients
Results are expressed as the
mean ± SD. P value indicated
for CAD-DM versus
CAD?DM
CAD Coronary artery disease,
DM type 2 diabetes mellitus,
ACE angiotensin converting
enzyme, ARB angiotensin
receptor blockers, FPG fasting
plasma glucose, ND not
determined, OHD oral
hypoglycemic drugs
CTR, n = 25 CAD-DM, n = 10 CAD?DM, n = 15 P value
Age (years) 59.9 ± 12.7 63.7 ± 9.9 66 ± 11 0.579
BMI ND 26.8 ± 2 26.3 ± 5
Male gender, n (%) 12 (48) 7 (70) 9 (60) 0.470
Cardiovascular risk factors
CAD history (years) 0 10 ± 89 ± 8 0.578
Family history of CAD, n (%) 11 (44) 7 (70) 7 (47) 0.231
Hypertension, n (%) 12 (48) 4 (40) 9 (60) 0.284
Smoking, n (%) 6 (24) 3 (30) 6 (40) 0.607
Diabetes, n (%) 0 (0) 0 (0) 15 (100)
Duration of DM (years) 0 0 8 ± 7
Patients receiving insulin (%) 0 0 40
Patients receiving OHD (%) 0 0 100
FPG (mmol/l) 5.5 ± 0.7 6.3 ± 0.7 8.3 ± 4.6 0.048
HbA1c (%) ND ND 7.3 ± 0.6
Laboratory parameters
Cholesterol, total (mmol/l) 5.9 ± 1.3 4.4 ± 0.8 4.0 ± 1.4 0.283
LDL-cholesterol (mmol/l) 4.0 ± 1.2 2.1 ± 0.8 2.1 ± 0.9 0.16
HDL-cholesterol (mmol/l) 1.8 ± 1.0 1.2 ± 0.6 1.0 ± 0.3 0.127
Triglycerides (mmol/l) 1.8 ± 1.2 1.8 ± 0.4 2.1 ± 1.1 0.638
Medication at admission
Antiaggregatory therapy
(antiplatelet drugs) n (%)
11 (44) 7 (70) 7 (47) 0.231
Beta-blockers, n (%) 16 (64) 7 (70) 10 (67) 0.222
ACE-inhibitors/ARB, n (%) 12 (48) 6 (60) 7 (47) 0.688
Statins, n (%) 12 (48) 8 (80) 12 (80) 0.687
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123CAD, metabolic disease or chronic illness (n = 25).
Baseline clinical features of CTR, CAD-DM and
CAD?DM patients are presented in Table 1. There were
no signiﬁcant differences between three groups with
regards to age, gender, BMI, presence of cardiovascular
risk factors and medication. CAD?DM patients exhibited
higher fasting glucose level compared to CTR (P = 0.019)
and compared to CAD-DM group (P = 0.048).
Monocyte isolation and migration
Blood samples (100 ml) were collected from all subjects.
Monocytes were isolated by Percoll gradient centrifugation
based on a previously described protocol [40]. The purity
of isolated monocytes was C90% as determined by ﬂow
cytometry. Monocytes were subjected to chemotaxis assay
using the modiﬁed Boyden chamber [2]. Brieﬂy, different
concentrations of Shh or Ihh were placed in the bottom
well and monocytes were placed in the top well. Polycar-
bonate membranes with a pore diameter of 5 lm (Nucle-
pore) were used. The chambers were incubated at 37Ci n
the presence of 5% CO2 for 90 min. Afterwards ﬁlters were
removed, ﬁxed, stained with Giemsa dye before scraping
off cells at the upper side of the ﬁlter membrane and ﬁve
high-power ﬁelds were counted for each sample (primary
magniﬁcation 209). To differentiate between chemotaxis
and chemokinesis, checkerboard analysis was performed
by placing various dilutions of Shh in both the lower and
upper wells of the modiﬁed Boyden chamber. To study the
effect of different inhibitors on Shh-induced migration,
monocytes were pretreated with a speciﬁc inhibitor of Hh
signaling, cyclopamine (CP, 10 lM), the PI3K inhibitor,
LY294002 (10 lM), or a speciﬁc inhibitor of Gai/o, per-
tussis toxin (PTX, 100 ng/ml) for 15 min before the che-
motaxis assay.
RT-PCR analysis
Total RNA from monocytes or HUVEC (used as a
control) was isolated using RNeasy Protect Mini Kit
from QIAGEN. For reverse transcription, 1 lg of total
RNA was converted into cDNA by AMV reverse
transcriptase at 37C for 1 h in a 20 ll RT reaction. All
the primers used in this study and PCR conditions are
listed in Table 2.
Flow cytometry analysis
Expression of Ptc on leukocytes was analyzed by ﬂow
cytometry. Leukocytes were stained with anti-Ptc primary
antibodies (Santa Cruz Biotechnology). Double staining
with CD14-FITC (Becton Dickinson) and Ptc/anti-goat-PE
antibody was performed to conﬁrm the expression of both
proteins on monocytes. The analysis was carried out on a
FACSCalibur ﬂow cytometer using the CellQuest software
(Becton Dickinson).
Table 2 Primers and conditions used for RT-PCR
Gene Sequence (50–30) Annealing temperature
and cycle number
Fragment size (bp)
Shh FW: ACT GGG TGT ACT ACG AGT CCA AGG 63C, 50 cycles 211
RV: AAA GTG AGG AAG TCG CTG TAG AGC
Ihh FW: CTA CGC CCC GCT CAC AAA G 60C, 30 cycles 376
RV: GGC AGA GGA GAT GGC AGG AG
Dhh FW: ACCAATCTACTGCCCCTGTG 62C, 30 cycles 246
RV: GTTGTAGTTGGGCACGAGGT
Smo FW: CAG GAC ATG CAC AGC TAC ATC G 65C, 30 cycles 380
RV: CCA CAA AGA AGC ACG CAT TGA C
Ptc FW: CCA TGT TCC AGT TAA TGA CTC 55C, 30 cycles 462
RV: ACA TCA TCC ACA CCA ACA
SUFU FW: CCT CCA GAT CGT TGG TGT CT 55C, 30 cycles 195
RV: CTG TCT CGA TGC CTT TGT CA
Gli-1 FW: GGG ATG ATC CCA CAT CCT CAG TC 60C, 50 cycles 386
RV: CTG GAG CAG CCC CCC CAG T
Gli-2 FW: ACC GCT GCT CAA AGA GAA TG 64C, 50 cycles 507
RV: CCC ACT GCC ACT GAA GTT TTC C
Gli3 FW: CCT CAA AGC GGG CCG CCT GC 64C, 50 cycles 406
RV: CAG GTT GTT GTT GGA CTG TGT GC
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Cross sections of human aortic atherosclerotic plaque were
deparafﬁnized, dehydrated, and permeabilized with 0.05%
Tween in citrate buffer, and then blocked with normal
horse serum. Further, they were incubated with primary
polyclonal antibodies for Ptc (1:25, goat polyclonals; Santa
Cruz Biotechnology Inc) or CD68 (1:100, mouse mono-
clonal; DakoCytomation). A biotinylated horse anti-mouse
and anti-goat IgG (1:1,000) was incubated followed by
incubation with streptavidin/HRP antibodies and visualized
with AEC staining solution. Consecutive sections were
stained and the results of Ptc staining and CD68 staining
were merged for demonstration of coexpression. The nega-
tive controls included substitution of primary antiserum for
PBS.
Statistical analysis
Statistical analysis was performed with SPSS12.0.1 statis-
tical software. Categorical variables are presented as per-
centage of patients and compared by Fisher’s exact test.
Data are presented as the mean ± standard deviation (SD).
In addition, the medians (in the ﬁgure: median as line,
25th–75th percentiles as box, 5th–95th percentiles as
whiskers) are given in case of non-normally distributed
results. CTR, CAD-DM and CAD?DM patients were
compared using a Mann–Whitney U test with Bonferroni
correction. Values of P\0.05 were considered statisti-
cally signiﬁcant.
Results
Human peripheral monocytes express components
of Hh signaling
Initially, we examined human monocytes for the expres-
sion of components involved in Hh signaling including the
ligands Shh, Dhh and Ihh, the receptor Ptc, co-receptor
Smoothened (Smo), hedgehog interacting protein (Hip),
suppressor of Fused (SUFU), transcription factors Gli 1, 2
and 3. We carried out RT-PCR on RNAs prepared from
isolated human peripheral monocytes. RNA from HUVEC
was used as a positive control. We conﬁrmed the expres-
sion of Ihh, Dhh, Ptc, Smo, SUFU and Gli3 genes on
monocytes, but could not detect the expression of Shh, Hip,
Gli1 and Gli2 (Fig. 1a).
To conﬁrm the surface expression of Hh receptor Ptc
protein, ﬂow cytometric analysis was performed. Double
staining of the monocyte fraction with the monocyte mar-
ker CD14 and Ptc antibodies demonstrated that 95% of the
monocytes were positive for Ptc (Fig. 1b). These results
suggest that monocytes can be susceptible to Hh protein
stimulation.
Chemotactic properties of Shh
Monocytes isolated from the blood of control subjects were
assessed for their ability to migrate to Shh. Shh-induced
monocyte chemotaxis with a bell-shaped dose–response
curve, whereby stimulation with 0.01 lg/ml Shh stimulated
migration to 123.8 ± 34% (P = 0.622), stimulation with
0.1 lg/ml Shh led to 132.4 ± 26% (P = 0.093), while
stimulation with 1 lg/ml resulted in 172.5 ± 90% of
baseline (P\0.005), and 2.5 lg/ml Shh in 153.1 ± 60%
(P = 0.006) (Fig. 2a, c). Based on these results, we used
1 lg/ml Shh for all further experiments presented. Similar
results were observed when Ihh was used to induce
monocyte migration (Fig. 2B). However, the optimal
concentration for Ihh was 2.5 lg/ml. In the checkerboard
control experiment, when Shh was added to both upper and
lower wells, monocyte chemotaxis was not observed
(Fig. 2a). These data indicate that a concentration gradient
of Shh is required for monocyte chemotaxis.
Fig. 1 Expression of Hedgehog signaling components in human
monocytes. a RT-PCR analysis of the Shh, Ihh, Dhh, Smo, Ptc,
SUFU, Hip, Gli1, Gli2, Gli3, and actin gene expression on human
peripheral monocytes and HUVEC (used as a positive control). The
results are representative of three independent experiments. b Flow
cytometric analysis of Ptc expression on monocytes. Left panel
Isotype (negative) control. Right panel Puriﬁed monocytes were
double-stained with anti-Ptc antibodies and CD14 antibodies as a
marker for monocytes
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123To check the speciﬁcity of Shh-induced chemotaxis, we
pretreated isolated monocytes with CP, a selective inhibitor
of Hh signaling. The steroidal alkaloid CP speciﬁcally
inhibits the Hh pathway by direct binding to Smo and
induces a conformational shift leading to Smo inactivation
[8]. This pretreatment of monocytes had no effect on
chemokinesis. However, CP completely inhibited Shh-
induced chemotaxis (Fig. 3a). CP did not abrogate mono-
cyte chemotaxis induced by MCP-1 (data not shown).
These results indicate that the chemotactic activity of Shh
is speciﬁc and dependent on Smo activity.
Requirement of G-proteins and PI3 K for Shh-induced
chemotaxis of monocytes
Intracellular chemokine receptor signaling depends on
coupling to heterotrimeric G-proteins, usually of the Gi-
type [19]. To assess whether Shh-induced chemotaxis is
mediated by Gi proteins, we pretreated monocytes with
pertussis toxin (PTX), a speciﬁc inhibitor of Gai/o, for
15 min and stimulated with an optimized concentration of
Shh (1 lg/ml). Pretreatment with PTX did not affect che-
mokinesis (89 ± 22%, P = 0.974); however, Shh-induced
chemotaxis of monocytes (165 ± 25%) was impaired by
PTX to 62.1 ± 30% (P\0.001, Fig. 3b). These data
suggest that Shh-mediated chemotaxis requires signaling
via the activation of Gai.
The binding of a chemoattractant to its receptor leads to
an increased activation of PI3K and cell polarization [34].
Recent studies reported that Shh also regulates some pro-
cesses through the PI3K/Akt pathway [17, 31]. To inves-
tigate the role of the PI3K pathway in Shh-induced
migration, we pretreated monocytes with the speciﬁc PI3K
inhibitor LY294002 for 15 min prior to the chemotaxis
assay. LY294002 inhibited both chemokinesis and che-
motaxis induced by Shh (Fig. 3c). Chemokinesis was
reduced from 100 to 52 ± 26% (P = 0.001), while Shh-
induced chemotaxis was signiﬁcantly decreased from
165.7 ± 16 to 35 ± 13% (P\0.005). Overall, our data
suggest that Shh-mediated chemotaxis of monocytes
involves PI3K and Gi proteins.
Diabetes mellitus type 2, but not CAD, negatively
affects Shh-induced migration of human peripheral
monocytes
Abnormalities in monocyte function may be responsible
for impaired collateral growth in certain patient subsets
[10]. It has been demonstrated that CAD patients with DM
have a reduced ability to develop collateral blood vessels
Fig. 2 Both Shh (a) and Ihh (b)
induce migration of human
monocytes ex vivo in a
concentration-dependent
fashion. Monocytes were
isolated from peripheral blood
samples (n = 25) and the
chemotactic response was
measured using a modiﬁed
Boyden chamber. Five high-
power ﬁelds were counted for
each sample (primary
magniﬁcation 920). Statistical
signiﬁcance was evaluated
using the unpaired Student’s t
test. The median values are
plotted on the graphs. *
P B 0.005. c Monocyte
migration in the presence (right)
or absence (left) of Shh (1 lg/
ml). The representative
photograph of the stained ﬁlter;
monocytes are detected on the
lower surface of the ﬁlter
following migration through the
pores
Basic Res Cardiol (2010) 105:61–71 65
123[42]. To check whether the Hh signaling pathway is
affected by CAD and DM, we compared the migratory
response to Shh of monocytes isolated from CTR,
CAD-DM and CAD?DM patients.
Shh (1 lg/ml) did stimulate migration of monocytes
from CAD-DM patients. However, the stimulation of
migration was lower in CAD-DM compare to CTR
(134 ± 44 vs. 172.5 ± 90%, P = 0.354). In diabetic
patients (CAD?DM) Shh failed to induce mono-
cyte migration (94.3 ± 27 vs. CTR, P\0.001 and vs.
CAD-DM, P = 0.033; Fig. 4a).
The chronic inﬂammation associated with DM could
affect the expression of the Hh receptor Ptc on monocytes,
which might explain the altered chemotactic response in
DM. The RT-PCR-based analysis of Ptc expression on
monocytes from CTR, CAD-DM and CAD?DM patients
revealed that Ptc expression was upregulated in both
CAD-DM and CAD?DM (Fig. 4b). The fold of increase
was 5.4-fold for CAD-DM patients (P = 0.045) and
11-fold for CAD?DM (P = 0.004). In contrast, there were
no statistically signiﬁcant differences in expression of Ihh
(Fig. 4c), Dhh, Smo, Gli3, Hip and SUFU mRNA (data not
shown). Thus, alterations of Hh signaling in CAD-DM
and CAD?DM monocytes could only be observed at the
level of the receptor Ptc.
A high interindividual variability of Ptc expression in
monocytes from CAD-DM patients was noticed.
Therefore, we checked the correlation of monocyte
migration with Ptc expression level for these patients. The
results demonstrated the tendency that monocytes showing
reduced migration express higher level of Ptc. However,
this correlation was not statistically signiﬁcant.
Upregulation of the receptor Ptc is a direct indication of
Hh signaling activation, since it is a Hh target gene. Gli1
and Hip1 are two other Hh target genes. To conﬁrm the
possible activation of Hh signaling in monocytes from
diabetic patients, we analyzed Gli1 and Hip1 mRNA
expression on monocytes from different patient groups.
Neither Gli1 nor Hip1 mRNA expression in monocytes
from different patient groups was detected (data not
shown). Thus, our novel data indicate signiﬁcant altera-
tions of the Hh signaling primarily at the level of receptor
Ptc.
The receptor Ptc colocalizes with macrophages
in human atherosclerotic plaques
Diabetes mellitus is often associated with accelerated ath-
erosclerosis, which is critically mediated by monocytes/
macrophages. We performed staining with speciﬁc Ptc
antibodies and CD68 antibodies to check whether macro-
phages in atherosclerotic lesion express Ptc. Our data
clearly demonstrate the colocalization of receptor Ptc with
CD68, a marker for macrophages (Fig. 5, merge). Non-
Fig. 3 a Cyclopamine (CP)
inhibits Shh-induced monocyte
chemotaxis. Monocytes were
pretreated with CP (10 lM) for
15 min and chemotactic
response to Shh (1 lg/ml) was
measured using the modiﬁed
Boyden chamber. Statistical
signiﬁcance was evaluated
using the unpaired Student’s t
test. The median values are
plotted on the graphs;
* P\0.005, n = 11. Both Gi
inhibitor PTX (100 ng/ml, b)
and PI3K inhibitor LY294002
(10 lM, c) block Shh-induced
(1 lg/ml) chemotaxis of
peripheral monocytes. The
median values are plotted on the
graphs; * P\0.005, n = 11
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123immune IgG did not show any positive staining (data not
shown).
Discussion
In this study, we present data supporting a role for Shh/Ihh
in stimulation of monocyte chemotaxis. We have not used
Dhh for our experiments, because up to now there is no
evidence that Dhh is expressed in vascular endothelial cell
or vascular smooth muscle cells. Our data demonstrate that
both Shh and Ihh stimulate monocyte chemotaxis at the
optimal concentration for Shh 1 lg/ml and for Ihh 2.5 lg/
ml. Chemotaxis induced by Shh was speciﬁc and Smo-
dependent. Moreover, Shh activates classical intracellular
signal transduction pathways related to cellular migration
such as G-protein-coupled speciﬁc receptor pathways or
PI3K.
Fig. 4 a Shh-induced (1 lg/ml) chemotaxis of monocytes isolated
from CTR, CAD-DM or CAD?DM patients. The median values are
plotted; ns; nonsigniﬁcant versus unstimulated control. The median
(line), 25th and 75th percentiles (box), 5th and 95th percentiles
(whiskers) are presented. * P\0.005. The level of Ptc (b), and Ihh
(c) gene expression on monocytes isolated from CTR, CAD-DM and
CAD?DM patients. RNA isolated from monocytes was subjected to
RT-PCR. b-actin cDNA product served as internal standard to
normalize Ptc and Ihh. Signal intensity of Ptc and Ihh mRNA bands
was quantiﬁed by densitometry and compared with the internal
standard b-actin
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effect, is rather high in comparison with other known
chemoattractants such as MCP-1, MIPs and fractalkine
[25]. This may be explained as follows: Hh proteins
undergo two posttranslational processing events that result
in the covalent addition of cholesterol at the C-terminus
[30] and a long-chain fatty acid on the N-terminal cysteine
[34]. In addition to tethering the protein to the surface of
the cell in which it is synthesized, lipid modiﬁcation
greatly stimulates biological activity of the protein [28, 37].
Recombinant Shh used in these experiments was expressed
and puriﬁed from E. coli, where it does not undergo those
hydrophobic modiﬁcations. Recombinant Shh is therefore
less potent that natural modiﬁed proteins [38].
Our current study was not designed to identify the
physiological source of Shh that could inﬂuence monocyte
migration. Nevertheless, it has already been demonstrated
that vascular endothelial [4] and smooth muscle cells [25]
express Shh. It is thus conceivable that Shh expressed in
these cells may attract monocytes into a vessel. Moreover,
altered expression of Shh has been reported in a variety of
different pathological conditions such as tumorgenesis [14]
and ischemic injury [21]. Expression of both Shh and Ptc
was increased in cardiac ischemia. Shh expression was
upregulated at the sites of inﬂammation [29] and repair
[41].
Recent reports have indicated that abnormalities in
monocyte function may be one of the factors responsible
for reduced vessel growth and vascular complications in
certain patient groups [39]. Monocytes from diabetic
patients show a migration defect [40], reduced phagocy-
tosis [20, 26] and increased adhesion to endothelial cells
Fig. 5 Expression of Ptc in an
advanced, stable human aortic
atherosclerotic lesion.
Immunohistological analysis
demonstrates that
approximately 80% of
macrophages were positive for
both Ptc and CD68 (merge).
Brown color indicates
positivity. Sections were
counterstained with
hematoxylin. Magniﬁcation for
upper panels is 910 and for
lower panels (magniﬁed inserts)
is 940
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diabetic patients do not respond to Shh at the most efﬁcient
concentration in CTR, i.e. 1 lg/ml. This impaired chemo-
tactic response was associated with a 11-fold increase of
Ptc mRNA expression in diabetic monocytes. The increase
of Ptc expression could be also observed for some CAD-
DM patients; however, the difference in expression was not
statistically signiﬁcant in comparison to control subjects (3
patients from 10 had higher level of Ptc expression com-
pared to control). However, there was no signiﬁcant dif-
ference in mRNA expression between different groups for
ligands Ihh and Dhh and downstream Hh signaling com-
ponents Smo and SUFU. Previously, impaired chemotactic
response of monocytes associated with increased surface
expression of receptors was observed for patients with DM
type 1 [5]. Similar effect was observed for blood mono-
cytes from epithelial ovarian cancer. Notwithstanding the
increased levels of CCR2 and CCR5 detected on ascitic
monocytes, in comparison to that of normal donors,
migration response to their ligand RANTES was impaired
[16].
Diabetes mellitus type 2 is often associated with obesity.
It has been reported that the Hh signaling pathway was less
active in obese compared to lean mice. Two models have
been tested, mice invalidated in leptine (ob/ob) and high-
fat diet induced obesity. So far all experiments leading to a
stimulation of Hh signaling in vivo result in an enlarged
body mass and conversely, an inhibition of the pathway
prevents weight gain [11]. We did not observe signiﬁcant
differences between CAD-DM and CAD?DM with
regards to BMI. Therefore, it is unlikely that an excess of
adipose mass, which characterizes obesity and is often
associated with diabetes, may play a role in disregulation
of Hh pathway.
Moreover, diabetes mellitus is also accompanied by a
systemic low-grade inﬂammation and it is an important
factor in accelerating atherosclerosis. It has been reported
that LPS-induced Ptc expression in macrophages after 18 h
in culture [41]. Thus, low-grade inﬂammation could
upregulate expression of Ptc on circulating monocytes of
diabetes patients. In addition, it has been previously shown
in Drosophila that to achieve maximal pathway activity,
large excess (more than 50-fold) of Smo over Ptc is
required [36]. If similar regulation of Hh signaling applies
to the human system, the strong upregulation of Ptc and
preserved expression level of Smo in diabetic patients
could explain the observed defect in Hh signaling.
Monocytes/macrophages are recognized as one of the
principal cell types in the pathology of atherosclerosis [43,
44]. Accumulating evidence suggests that the Hh pathway
is involved in peripheral immunity and tissue remodeling
[21, 23]. Expression of Shh and Ptc is upregulated in small
bowel allografts undergoing chronic rejection. Systemic
treatment with a neutralizing anti-Shh antibody reduced
tissue remodeling, ﬁbrosis and vascular occlusion of the
intestinal grafts [7]. The cells that expressed Ptc in the
intestinal grafts undergoing chronic rejection were mainly
macrophages. In a recent study using an ApoE
-/--based
mouse model of atherosclerosis, inhibition of Shh using
speciﬁc antibodies resulted in a pro-atherosclerotic phe-
notype secondary to enhanced lipid uptake in macrophages
[3]. Our novel data do support the idea that inhibition of
Shh may be pro-atherogenic. Macrophages in human ath-
erosclerotic plaques express high levels of receptor Ptc.
The diabetes-related inhibition of macrophages may pre-
vent their clearance from atherosclerotic plaques. This
could be a novel molecular mechanism promoting athero-
sclerosis; however, its functional relevance and extent in
the pathogenesis of human atherosclerosis remains to be
determined.
Thus, our data represent the ﬁrst example of an endo-
genous metabolic abnormality, namely DM, which is
associated with a functional inhibition of the Hh signaling
pathway. Likewise, this impaired monocyte function is
likely to be associated with impaired arteriogenesis and
impaired wound healing [35, 39]. Identiﬁcation of novel
signal transduction pathways regulating monocyte chemo-
taxis can indicate unique targets for preventive therapies
for treatment of chronic inﬂammatory diseases.
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